1. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study
- Author
-
Jennifer S. Gewandter, Chinazom Ibegbu, Noah Kolb, Rachel A. Kitt, Jenna Chaudari, Joy Burke, Jennifer Serventi, Eva Culakova, Mohamedtaki Abdulaziz Tejani, Nimish Mohile, and Kathleen A. Sluka
- Subjects
Male ,medicine.medical_treatment ,Antineoplastic Agents ,Transcutaneous electrical nerve stimulation ,Article ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Randomized controlled trial ,law ,Neoplasms ,Sensation ,Humans ,Medicine ,030212 general & internal medicine ,Chemotherapy ,business.industry ,Peripheral Nervous System Diseases ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Peripheral neuropathy ,Oncology ,Chemotherapy-induced peripheral neuropathy ,030220 oncology & carcinogenesis ,Anesthesia ,Neuropathic pain ,Quality of Life ,Transcutaneous Electric Nerve Stimulation ,Feasibility Studies ,Female ,Neurotoxicity Syndromes ,business - Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in approximately 68% of patients who receive neurotoxic chemotherapy and lasts at least 6 months post-chemotherapy in approximately 30% of individuals. CIPN is associated with decreased quality of life and functional impairments. Evidence suggests that CIPN symptoms are caused, in part, by enhanced excitability and impaired inhibition in the central nervous system. Transcutaneous electrical nerve stimulation (TENS) decreases pain by counteracting both of these mechanisms and is efficacious in other conditions associated with neuropathic pain. This single-arm study (n=29) assessed the feasibility of investigating TENS for CIPN after chemotherapy completion using a wireless, home-based TENS device. Eighty-one percent of eligible patients who were approached enrolled, and 85% of participants who received the TENS device completed the primary (6-week) study term. Qualitative interview data suggest that use of the device on the continuous setting that automatically alternates between 1-hour stimulation and rest periods for 5 hours/day would be acceptable to most participants. Significant (i.e., p
- Published
- 2018
- Full Text
- View/download PDF